Adenocarcinoma of lung
Conditions
Interventions
experimental group:Chemotherapy + Qilu Buxue Granule
control group:Chemotherapy +placebo
Sponsors
Chongqing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. There is no bone marrow suppression in patients with lung adenocarcinoma, and the researchers have determined that the chemotherapy regimen is acceptable. 2. Those who can accept platinum-containing regimens (NP, GP, AP regimens) are expected to be able to observe two cycles of chemotherapy. 3. Patients receiving the platinum-containing regimen include: as a chemotherapy regimen for patients with advanced adenocarcinoma, post-operative adjuvant chemotherapy for patients with completely resected stage II-III adenocarcinoma, and preoperative short-term neoadjuvant chemotherapy for patients with resectable stage III adenocarcinoma. 4. Peripheral white blood cells (> 4.0x10^9/L), neutrophils (> 2.0x10^9/L) and ZPS (ECOG) scores (< 2) before chemotherapy. 5. The patient's vital signs were stable before chemotherapy, the laboratory examination indexes were stable, the estimated survival time was more than 3 months. 6. Aged 18-75 years; 7. Volunteer to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. With a history of bone marrow depression of degree III-IV in the past; 2. Patients receiving concurrent radiotherapy or those unable to accept the above-mentioned chemotherapy regimen due to disease progression; 3. Patients with liver cirrhosis, hypersplenism and hematological diseases; 4. Patients with with obvious infection; 5. Weight loss of more than 15% in the last month; 6. Allergic constitution, allergic to any known ingredient in the research drug; 7. Those who have participated in other clinical trials in the past one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| white blood cell;Neutrophils; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet;Red blood cell;Hemoglobin;TCM Symptom Score; | — |
Countries
China
Contacts
Public ContactZhang Ying
Outcome results
None listed